

- 3 -

Li et al.  
Appl. No. 09/515,513***Remarks******I. Support for Amendment***

The foregoing amendment is believed to place the claims into condition for immediate allowance or into better condition for consideration on appeal. Moreover, the amendment merely clarify Applicants' invention, per Examiner's suggestion, and does not raise new issues for consideration by the Examiner. Support for the foregoing amendment to the claims may be found throughout the specification (e.g. page 25, lines 15-24). Entry of the present amendment is respectfully requested.

***II. Status of the Claims***

Upon entry of this amendment, claims 47-63 are pending in the application, with claim 47 being the independent claim.

***VIII. Conclusion***

Applicants respectfully request that the Examiner reconsider all presently outstanding rejections and that they be withdrawn. Applicants believe that the foregoing amendment places the present application in condition for allowance.

①


- 4 -

*Li et al.*  
Appl. No. 09/515,513

If the Examiner believes, for any reason, that personal communication could expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond  
Attorney for Applicants  
Registration No. 32,893

Date: May 3, 2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

SKGF\_DC1:9036.1

D

- 5 -

Li *et al.*  
Appl. No. 09/515,513**Version with markings to show changes made*****In the Claims:***

47. (Once amended) A method for synthesizing one or more cDNA molecules or a population of cDNA molecules, comprising mixing at least one mRNA template, poly A RNA template or population of such templates with at least one polypeptide having reverse transcriptase activity and an inhibitor of the polypeptide having reverse transcriptase activity, under conditions that inhibit, prevent, reduce or substantially reduce the synthesis of non-specific cDNA products when compared to when said inhibitor is absent; and synthesizing one or more cDNA molecules or a population of cDNA molecules.

SKGF\_DC1:9036.1

D